Search

everythinglearnresearchcommunity

for

Search:↓

The new compound may be a safer alternative to finasteride for prostate protection.

Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

Tamoxifen effectively treats gynecomastia without causing impotence.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

New methods to make oxasteroids show promise for medical treatments like osteoporosis and breast cancer.

SARMs show promise but need more evidence to prove they're better than traditional androgens.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common side effect of hormone treatments for cancer.

Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

Letrozole reduces seizures but not brain damage in mice.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

Tamoxifen can cause total hair loss but its benefits outweigh this side effect.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.

RU 58841 may treat acne, hair loss, and excessive hair growth.